Brentuximab vedotin
C25002
Phase 2 small_molecule completed
Quick answer
Brentuximab vedotin for Relapsed or Refractory Hodgkin Lymphoma is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Relapsed or Refractory Hodgkin Lymphoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed